Prognostic/predictive value of 207 serum factors in colorectal cancer treated with cediranib and/or chemotherapy.

ABSTRACT:

Background

The prognostic and predictive value of multiple serum biomarkers was evaluated using samples from a randomised phase III study (HORIZON II) investigating chemotherapy with or without cediranib in metastatic colorectal cancer (mCRC).

Methods

Baseline levels of 207 protein markers were measured in serum samples from 582 HORIZON II (FOLFOX/XELOX plus cediranib 20 mg (n=330) or placebo (n=252)) patients. Median baseline values of each biomarker were used to categorise patients as high or low. Markers were then assessed for their association with efficacy, defined by progression-free survival (PFS) and overall survival (OS). A generalised boosted regression model identified markers of particular interest.

Results

Correlation of protein levels with PFS and OS sug

SUBMITTER: Spencer SK 

PROVIDER: S-EPMC3844909 | biostudies-literature | 2013 Nov

REPOSITORIES: biostudies-literature